debate right now over whether low-dose versions of Mevacor and Pravachol should be sold OTC

There's lots of debate right now over whether low-dose versions of Mevacor and Pravachol should be sold OTC.

The FDA is holding meetings...and considering it for the U.S. Canadian officials are watching this closely.

Several medical and pharmacy associations strongly support it.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote